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LETTER TO THE EDITOR
Coccygeal Fracture Pain Cured by Sacral
Neuromodulation: A Case Report
To the Editor:
There are many painful syndromes that are often difficult to treat.
One option is electrotherapy, also known as neurostimulation. The
Gate Control Theory first described by Melzack and Wall (1) in 1965
postulated that nerves carrying painful peripheral stimuli and
nerves carrying touch and vibratory sensation both terminate in the
dorsal horn, which acts as the gate of the spinal cord. They hypoth-
esized that input to these nerves could“close the gate”to the painful
stimuli, thereby eliminating pain.
Based on the Gate Control Theory, Shealy et al. (2) in 1967 showed
success in treatment of chronic pain using the first spinal cord
stimulator. Continuing this work, Shimoji et al. (3) in 1993 created
epidural spinal cord stimulation (SCS) that displayed analgesic
properties.
SCS use has been widespread, and is Food and Drug Administra-
tion (FDA) approved for numerous conditions. In addition to
cervical, thoracic, and lumber stimulators, there is also sacral
neuromodulation.
Sacral neuromodulation (InterStim®, Medtronic, Minneapolis,
MN) has been indicated by the FDA for the treatment of urinary
urgency, urinary frequency, and fecal incontinence. It is the only
approved sacral neuromodulator. However, very little data exist on
its use for chronic pain or lower back pain. We describe a case where
InterStim was used to treat urinary urgency/frequency symptoms
and incidentally relieved chronic lower back pain from a previous
pelvic fracture.
CASE REPORT
A 74-year-old G2P2 postmenopausal female presented with
long-standing urge-dominant mixed urinary incontinence who
previously failed two anticholinergic medications, tolterodine and
darifenacin. She also underwent one year of pelvic floor physical
therapy with little improvement. She received an InterStim Periph-
eral Nerve Stimulation Phase I with incision and implantation of
bilateral tine quadripolar lead electrodes into the S3 foraminae
with fluoroscopic guidance under conscious sedation with local
anesthesia in December 2008. The placement was successful by
patient identification of sensation, great toe flexion, and bellowing
of the anus noted. She experienced a suboptimal urgency
response (defined as <50% reduction in symptoms), but pro-
ceeded to InterStim Phase II with incision and subcutaneous
implantation of sacral nerve neurostimulator with electronic analy-
sis and complex programming with the left lead as that side had a
great reduction in symptoms. She elected to continue with the
InterStim implantation because it significantly improved her
chronic coccygeal pain that resulted from a motor vehicle-induced
pelvic fracture, 25 years prior. She was so used to this debilitating
pain, which sometimes required her to have to “crawl to the bath-
room at night,” that she failed to inform us of this medical condi-
tion prior to implantation. Her daily pain rating went from an
8–10/10 to 2–4/10 on the visual analog scale. A sacral x-ray con-
firmed correct placement of the lead at the S3 level on that
patient’s left (Figs 1 and 2).
She continued to have daily episodes of leakage of urine and
began tolterodine again to help with urge symptoms, but greatly
desired the InterStim kept on because of considerable coccygeal
pain relief. The medication was subsequently discontinued as it did
not reduce her urge symptoms.
The patient subsequently lost the remote device for the InterStim
two months after placement and it was turned off for several
months. She noted prompt return of her chronic coccygeal pain
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Figure 1. Lateral sacral x-ray showing correct InterStim lead placement at S3
level.
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after losing the remote. After presenting to the office and obtaining
a new remote with the device turned on, the patient stated that she
again felt immediate relief from her pain.
She underwent collagen injections in November 2009 and
January 2010 (one year postimplant) for stress urinary inconti-
nence symptoms, with significant improvement in stress and urge
urinary incontinence symptoms for one week and then worsening
urge symptoms daily thereafter. The patient restarted pelvic floor
physical therapy and at the time stated that InterStim helps allevi-
ate urge symptoms at night, but does not reduce daytime symp-
toms. However, she still wants the InterStim kept on due to the
substantial relief of her chronic coccygeal pain from the previous
pelvic fracture.
She subsequently had Botulinum-A Toxin (Botulinum-A Toxin
(Botox®, Allergen Pharmaceuticals, Irvine, CA, USA) bladder injec-
tions for worsening urge symptoms in March 2011 (2.5 years
postimplant). As of May 2012 (3.5 years postimplant), she reports
that her urge symptoms are significantly improved and her
coccygeal pain is still controlled with the continued use of the
InsterStim.
DISCUSSION
SCS has incomplete coverage for many areas of the body, includ-
ing, but not limited to, low back, buttocks, feet, groin, pelvis, and
neck. The S2-5 dermatomes are supplied by pathways that are
somatotopically deep in the spinal cord and are often times difficult
to reach with SCS (4).
Peripheral nerve stimulation works by activating inhibitory inter-
neurons as well as primary afferent delta fibers, and has the poten-
tial to recruit more nerve fibers than SCS. SCS has to penetrate
through multiple dural layers as well as cerebrospinal fluid, and the
primary afferent delta fibers are not accessible (5).
Chronic pain disorders are more common among women than
men. Women also experience increased frequency of pain as well as
higher disability rates and greater allocation of healthcare resources
(5). Chronic pain in the sacral area has traditionally been difficult to
control, and the unique anatomy in this region may contribute.
Many chronic pelvic pain conditions are suspected to be neuro-
pathic in nature, including coccygodynia; however, this has not
been proven (5). This is further supported by the fact that there are
extremely limited medical and/or surgical interventions that allevi-
ate pain in a majority of patients (6). Patients with pelvic pain typi-
cally respond best to bilateral S2 or S3 electrodes as opposed to
unilateral (4).
Alo et al. in 1999 (7) (Table 1) used selective nerve root catheters
in the epidural space for five chronic pain patients who failed
several types of conservative treatment and had at least one
abnormal objective finding. The chronic pain syndromes involved
ilioinguinal neuralgia, discogenic pain at L4-5, failed back syn-
drome, vulvodynia, and interstitial cystitis. Multielectrode systems
were placed in the thoracic, lumbar, and/or sacral areas. All
patients had >50% reduction in pain level, with their visual
analogs declining significantly after the seven-day trial and all
requested permanent implantation of a nerve root stimulation
system. They also postulated that sacral electrodes appeared less
vulnerable anatomically to patient movement than electrodes at
other levels, possibly because they are contained within the root
sleeve in the spinal canal.
Again in 1999, Alo et al. (8) reported a cohort of 80 patients with
36-month follow-up after lead placement, primarily in thoracic and
cervical regions with a majority diagnosed with low back and
extremity pain. They were initially given a single program after
multiple electrodes were placed, then given access for multiple
program stimulation with patient control. This allowed patients to
control their level of success and alleviate the all-or-nothing phe-
nomenon. Eighty percent of patients would have the procedure
again and 72% were still using the SCS system daily after 36
months.
In 2001, Alo and Mckay (9) published a case report of a 32-year-
old woman with interstitial cystitis with intractable 10/10 pain that
severely disrupted her quality of life. Two sacral nerve root stimula-
tor electrodes were placed at the S2-3 level bilaterally. During her
seven-day trial phase, she had increased bladder volumes,
decreased pain, and stopped all bladder pain and spasm medica-
tions. Her pain level was significantly reduced at 1/10 by the visual
analog scale. She subsequently underwent permanent implanta-
tion at the same level. At publication, patient was one year after
implantation, only requiring occasional use of the stimulator and
has rare symptoms, with her preinterstitial cystitis quality of life
restored. A literature search for coccygeal fracture or neuromodula-
tion revealed one case report of a female that had previously under-
gone InterStim implantation for urinary incontinence and also had
bilateral lower extremity pain and back pain from postlaminectomy
syndrome (10). In this case, however, the InterStim did not improve
her pain, but instead they used SCS at levels T8-T9-T10 which helped
both her urinary incontinence and relieved her pain completely. In
addition, they tried the InterStim vs. the SCS (turning one off and
then the other for two-month period) and they were equal in terms
of urinary continence symptom relief, but only the SCS improved
both her lower extremity and back pain.
Figure 2. Anterior-posterior sacral x-ray confirming lead placement at
patient’s S3 level, left side.
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Several papers referred to postoperative pain in terms of pain
after placement and did not refer to preoperative pain that was
relieved with InterStim. Pauls et al. reported a prospective study
that evaluated sexual function after InterStim implantation for
urinary incontinence; however, patients did not have a history of
chronic pelvic pain (11). There was a significant improvement in pain
during intercourse (p = 0.015).
Marinkovic et al. reported patients with interstitial cystitis and
painful bladder syndrome that had a significant improvement in
pain after sacral neuromodulation (p < 0.01) (12). Another paper
on interstitial cystitis by Peters et al. describes a moderate or
marked improvement in pain after InterStim implantation in treat-
ing chronic pain associated with interstitial cystitis refractory to
standard therapy (13). Finally, another paper by Peters et al. found
that 69% of their patients reported moderate or marked improve-
ment in pelvic pain also with interstitial cystitis (14).
Only one case report was found that discussed SCS for treatment
of coccygodynia after a coccygeal fracture, by Yakovlev and Resch
(15). A 37-year-old male with a two-year history of coccygodynia
after a closed sacral and coccygeal fracture as well as a rectal tear. He
received surgery for the perineal wound, but continued to experi-
ence pain after the fractures had healed. Two epidural leads were
placed with a satisfactory trial response. The final leads were placed
at T8, T9, and T10, with excellent pain relief reported. The pain no
longer required pain medications and his quality of life improved.
Our patient underwent a lateral sacral x-ray which confirmed
correct lead placement at the S3 foramina; however, the pudendal
and coccygeal nerve roots are closely related. The S3 nerve root
contributes to the pudendal nerve. S4 and S5 nerve roots supply the
coccyx, anus, and rectal areas. It is possible that our patient has
variant anatomy and that the S3 nerve root supplies a portion of the
coccygeal area, which would account for her pain relief associated
with the InterStim device.
The majority of pain that the sacral neuromodulation has previ-
ously treated has been chronic pelvic pain that is refractory to other
therapies, which often coexists with urinary incontinence or refrac-
tory interstitial cystitis. For these two indications, it appears that the
sacral neuromodulation has a significant improvement in pain. No
citations were found that described the use of sacral neuromodula-
tion in terms of coccygeal pain; only SCS has previously been used.
In conclusion, sacral neuromodulation has the potential for treat-
ment of coccygeal pain.
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